Abstract: The present disclosure is concerned with Clofarabine analogs for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanomas, gliomas, leukemias, lymphomas, chronic myeloproliferative disorders, myelodysplastic syndromes, myeloproliferative neoplasms, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Aspects of the invention relate to substituted aryl propylamino-oxy-analogs and uses thereof. Aspects of the invention relate to compositions that are inhibitors of ?-secretase and uses thereof for treating subjects having, or at risk of developing, Alzheimer's disease.

Abstract: The present invention provides a method of treating Alzheimer's disease using a compound of Formula (I). Also provided is a method of inhibiting the aggregation of amyloid proteins using a compound of the Formula (I) and a method of imaging amyloid deposits, as well as new compounds of Formula (I).

Abstract: The present invention provides a method of treating Alzheimer's disease using a compound of Formula I 1

Abstract: Benzoxazines of Formula (I) wherein R1 is C1-C6 alkyl, C2-C6 alkenyl, or (CH2)n phenyl, R2 is C3-C6 alkyl, R3 is hydrogen, halo, hydroxy, alkoxy, or alkylthio, R4 is hydrogen or alkyl, or a pharmaceutically acceptable salt thereof, are useful for treating movement disorders such as Parkinson's disease.

Abstract: The present invention provides a method of treating Alzheimer's disease using a compound of Formula I 1

Abstract: Disclosed are compounds of the Formula I 1

Abstract: Benzoxazines of Formula (I) wherein R1 is C1-C6 alkyl, C2-C6 alkenyl, or (CH2)n phenyl, R2 is C3-C6 alkyl, R3 is hydrogen, halo, hydroxy, alkoxy, or alkylthio, R4 is hydrogen or alkyl, or a pharmaceutically acceptable salt thereof, are useful for treating movement disorders such as Parkinson's disease.

Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, wherein R1 is hydrogen, lower alkyl, COOR7, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted arylalkyl, or (un)substituted heteroarylalkyl; R3 is hydrogen or lower alkyl; R2, R4, R5, and R6 independently represent hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, mono- or dialkylamino, carboxy, alkoxycarbonyl, carbamoyl, sulfamoyl, trifluoromethyl, or alkylthio; R7 is hydrogen or lower alkyl; and R8 is hydrogen or oxo. Also provided is a method for selectively antagonizing the M4 muscarinic receptor and a method for treating Parkinson's disease.

Abstract: Disclosed are compounds of the Formula I 1

Abstract: Disclosed are compounds of the Formula I 1

Abstract: This invention concerns certain 2-substituted-3,1-benzoxazin-4-ones and benzthiazinones as complement Clr protease inhibitors and antiinflammatory agents, pharmaceutical compositions containing them, methods of using them, and processes for their preparation.